Slingshot members are tracking this event:

Gilead (GILD) Releases Data From Four Phase 3 POLARIS Studies Evaluating Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 20, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Polaris 1, Polaris 2, Polaris 3, Polaris 4, Sofosbuvir, Velpatasvir, Voxilaprevir, Treatment-experienced, Genotype 1-6, Chronic Hcv